tiprankstipranks
Lytix Biopharma AS (DE:6BG)
FRANKFURT:6BG
Germany Market

Lytix Biopharma AS (6BG) Stock Price & Analysis

0 Followers

6BG Stock Chart & Stats

Day’s Range€0 - €0
52-Week Range€0.41 - €1.11
Previous Close€0.5
Volume0.00
Average Volume (3M)333.00
Market Cap
€20.93M
Enterprise Value€8.48M
Total Cash (Recent Filing)kr145.16M
Total Debt (Recent Filing)kr0.00
Price to Earnings (P/E)N/A
Beta0.58
May 15, 2024
EPS EstimateN/A
Next Dividend Ex-DateN/A
Expense RatioN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding40,068,319
10 Day Avg. Volume0
30 Day Avg. Volume333
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0

Financials

Annual

6BG FAQ

What was Lytix Biopharma AS’s price range in the past 12 months?
Lytix Biopharma AS lowest stock price was €0.41 and its highest was €1.11 in the past 12 months.
    What is Lytix Biopharma AS’s market cap?
    Currently, no data Available
    When is Lytix Biopharma AS’s upcoming earnings report date?
    Lytix Biopharma AS’s upcoming earnings report date is May 15, 2024 which is in 48 days.
      How were Lytix Biopharma AS’s earnings last quarter?
      Lytix Biopharma AS released its earnings results on Feb 29, 2024. The company reported -€0.04 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.04.
        Is Lytix Biopharma AS overvalued?
        According to Wall Street analysts Lytix Biopharma AS’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
          Does Lytix Biopharma AS pay dividends?
          Lytix Biopharma AS does not currently pay dividends.
          What is Lytix Biopharma AS’s EPS estimate?
          Lytix Biopharma AS’s EPS estimate for its next earnings report is not yet available.
          How many shares outstanding does Lytix Biopharma AS have?
          Currently, no data Available
          What happened to Lytix Biopharma AS’s price movement after its last earnings report?
          Lytix Biopharma AS reported an EPS of -€0.04 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
            Which hedge fund is a major shareholder of Lytix Biopharma AS?
            Currently, no hedge funds are holding shares in DE:6BG
            ---

            Lytix Biopharma AS Stock Smart Score

            Company Description

            Lytix Biopharma AS

            Lytix Biopharma AS is a clinical-stage biotech company engaged in developing cancer immunotherapies aimed at activating the patient's immune system to fight cancer. Its lead product, LTX-315, is an oncolytic peptide with the potential to personalize immunotherapy.
            ---
            Popular Stocks
            ---
            What's Included in PREMIUM?
            Make informed decisions based on Top Analysts' activity
            Know what industry insiders are buying
            Get actionable alerts from top Wall Street Analysts
            Find out before anyone else which stock is going to shoot up
            Get powerful stock screeners & detailed portfolio analysis